Free Trial
NYSE:BIO

Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

Bio-Rad Laboratories logo
$307.48 +1.99 (+0.65%)
As of 03:18 PM Eastern

About Bio-Rad Laboratories Stock (NYSE:BIO)

Advanced

Key Stats

Today's Range
$300.98
$307.64
50-Day Range
$241.64
$305.47
52-Week Range
$211.43
$387.99
Volume
100,521 shs
Average Volume
312,780 shs
Market Capitalization
$8.32 billion
P/E Ratio
26.21
Dividend Yield
N/A
Price Target
$333.50
Consensus Rating
Hold

Company Overview

Bio-Rad Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
84th Percentile Overall Score

BIO MarketRank™: 

Bio-Rad Laboratories scored higher than 84% of companies evaluated by MarketBeat, and ranked 155th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bio-Rad Laboratories has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Bio-Rad Laboratories is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Bio-Rad Laboratories has only been the subject of 4 research reports in the past 90 days.

  • Read more about Bio-Rad Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Bio-Rad Laboratories are expected to grow by 15.17% in the coming year, from $10.81 to $12.45 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bio-Rad Laboratories is 26.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 235.22.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bio-Rad Laboratories is 26.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.97.

  • Price to Book Value per Share Ratio

    Bio-Rad Laboratories has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Bio-Rad Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    6.06% of the float of Bio-Rad Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Rad Laboratories has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Bio-Rad Laboratories has recently increased by 11.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Bio-Rad Laboratories does not currently pay a dividend.

  • Dividend Growth

    Bio-Rad Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.06% of the float of Bio-Rad Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Rad Laboratories has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Bio-Rad Laboratories has recently increased by 11.00%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Bio-Rad Laboratories has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Bio-Rad Laboratories this week, compared to 7 articles on an average week.
  • Search Interest

    12 people have searched for BIO on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Bio-Rad Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bio-Rad Laboratories insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.06% of the stock of Bio-Rad Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    65.24% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bio-Rad Laboratories' insider trading history.
Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIO Stock News Headlines

URGENT: The Market's 3 Red Flags Are Flashing
The warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.tc pixel
Zacks Research Issues Pessimistic Estimate for BIO Earnings
FY2026 Earnings Estimate for BIO Issued By Zacks Research
See More Headlines

BIO Stock Analysis - Frequently Asked Questions

Bio-Rad Laboratories' stock was trading at $328.51 on January 1st, 2025. Since then, BIO stock has decreased by 7.1% and is now trading at $305.31.

Bio-Rad Laboratories, Inc. (NYSE:BIO) announced its quarterly earnings data on Thursday, July, 31st. The medical research company reported $2.61 EPS for the quarter, beating analysts' consensus estimates of $1.93 by $0.68. The firm's quarterly revenue was up 2.1% on a year-over-year basis.
Read the conference call transcript
.

Bio-Rad Laboratories subsidiaries include these companies: Dropworks Inc., Celsee, Raindance Technologies Limited, GnuBIO Inc., Bio-Rad AbD Serotec GmbH, Propel Labs - Cell Sorting System Division, QuantaLife, and others.

Bio-Rad Laboratories' top institutional investors include GAMMA Investing LLC and Rowlandmiller & PARTNERS.ADV. Insiders that own company stock include Andrew J Last, Michael Crowley, Timothy S Ernst, Dara Wright, James Barry and Ajit Ramalingam.
View institutional ownership trends
.

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Rad Laboratories investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
7/31/2025
Today
10/06/2025
Next Earnings (Estimated)
10/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NYSE:BIO
CIK
12208
Employees
7,700
Year Founded
1952

Price Target and Rating

High Price Target
$409.00
Low Price Target
$265.00
Potential Upside/Downside
+9.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
$11.73
Trailing P/E Ratio
26.07
Forward P/E Ratio
28.29
P/E Growth
N/A
Net Income
-$1.84 billion
Net Margins
12.50%
Pretax Margin
17.62%
Return on Equity
4.01%
Return on Assets
2.82%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
5.12
Quick Ratio
3.67

Sales & Book Value

Annual Sales
$2.55 billion
Price / Sales
3.24
Cash Flow
$10.40 per share
Price / Cash Flow
29.40
Book Value
$234.52 per share
Price / Book
1.30

Miscellaneous

Outstanding Shares
27,062,000
Free Float
22,237,000
Market Cap
$8.28 billion
Optionable
Optionable
Beta
0.97

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NYSE:BIO) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners